A phase I/II study of increasing doses of epirubicin (E) and docetaxel (D) plus pegfilgrastim (Pegf) for locally advanced (LABC) or inflammatory breast cancer (IBC): NCIC CTG MA.22. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Trudeau, ME
  • Clemons, MJ
  • Dent, RA
  • Kahn, HJ
  • Parissenti, AM
  • Chapman, JW
  • O'Brien, P
  • Jong, RA
  • Pritchard, Kathleen
  • Shepherd, LE

publication date

  • May 20, 2010